ArticleAmerican journal of clinical and experimental urology2025
RB1 and p53 are diagnostic markers for treatment-related neuroendocrine prostate cancer: a clinical and pathological analysis of 23 cases.
Article in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HO-1 Nuclear Interactome Implications in Neuroendocrine Transdifferentiation in Prostate Cancer.International journal of molecular sciences · 2026Article
- Pathologic and multi-omic characterization of de novo neuroendocrine carcinoma of the prostate: A single center experience.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synergistic interplay between RB1 deletions and TP53 mutations drives androgen deprivation therapy (ADT) resistance and neuroendocrine transdifferentiation in advanced prostate cancer, culminating in treatment-related neuroendocrine prostate cancer (t-NEPC). This investigation systematically examines the clinicopathological characteristics and immunohistochemical phenotypes of t-NEPC to enhance diagnostic accuracy and prognostic understanding. We conducted a retrospective analysis of 23 t-NEPC cases diagnosed at the First Affiliated Hospital of Zhejiang University School of Medicine (2013-2024). We collected comprehensive clinical data, including patient demographics, treatment history, and serum biomarker profiles. Immunohistochemical evaluation was performed to determine expression patterns of prostate-associated antigens, neuroendocrine markers, and tumor suppressor proteins RB1/p53. The cohort demonstrated a mean age of 70 years at initial prostate cancer diagnosis, with t-NEPC emerging after a median ADT duration of 18 months. Biochemical profiles revealed a characteristic dissociation between suppressed prostate-specific antigen (PSA) levels and elevated neuroendocrine markers alongside other tumor-associated antigens, including carcinoembryonic antigen (CEA). The immunohistochemical signature of lineage transdifferentiation, indicated by the loss of androgen receptor (AR) and the expression of neuroendocrine markers, provides critical diagnostic clues for this aggressive variant. Molecular alterations were prevalent, with RB1 loss detected in 78.26% (18/23) and p53 abnormalities in 82.61% (19/23) cases. Notably, a histologically confirmed t-NEPC case with neuroendocrine marker negativity exhibited RB1/p53 co-alterations, molecularly aligning with most neuroendocrine-positive cases. These findings substantiate that combined RB1/p53 aberrations serve as robust diagnostic indicators for t-NEPC, particularly in tumors exhibiting small cell carcinoma morphology without neuroendocrine marker expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.